{"Clinical Trial ID": "NCT01644890", "Intervention": ["INTERVENTION 1:", "NK105", "NK105 (65 mg/m^2) received on days 1, 8 and 15 of a 28-day cycle", "INTERVENTION 2:", "- Paclitaxel", "Paclitaxel (80 mg/m^2) received on days 1, 8 and 15 of a 28-day cycle"], "Eligibility": ["Incorporation criteria:", "Informed written consent of the patient, signed by herself.", "A metastatic or recurrent adenocarcinoma confirmed histologically in the breast.", "At the time of informed consent, 20 to 74 years of age.", "- Exclusion criteria:", "Previous systemic chemotherapy with taxan anticancers for metastatic or recurrent breast cancer."], "Results": ["Performance measures:", "\u00b7 Progression Free Survival", "PFS is defined as the period from the day of randomization to the first observation of the progression of the lesion or death of any cause. The progression of the disease is defined as PD according to RECIST Ver. 1.1.", "The assessment period extends from the day of randomization to the first observation of the progression or death of the injury.", "Time frame: baseline, every 6 weeks of the study treatment period, and end of study,", "Results 1:", "Title of arm/group: NK105", "Description of the arm/group: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle", "Total number of participants analysed: 211", "Median (95% confidence interval)", "Unit of measure: month 8.4 (7.0 to 9.9)", "Results 2:", "Title of the arm/group: Paclitaxel", "Description of the arm/group: Paclitaxel received (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle", "Total number of participants analysed: 211", "Median (95% confidence interval)", "Unit of measure: month 8.5 (6.9 to 11.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 34/214 (15.89 per cent)", "- Leucocytosis 0/214 (0.00 %)", "Atrial fibrillation 0/214 (0.00 %)", "Congestive heart failure 0/214 (0.00 %)", "Pericardial infusion 1/214 (0.47%)", "Category 0/214 (0.00 %)", "Macular fibrosis 0/214 (0.00 %)", "Constipation 2/214 (0.93%)", "Diarrhoea 2/214 (0.93%)", "Enterocolitis 0/214 (0.00 %)", "Ileus 1/214 (0.47%)", "Nausea 3/214 (1.40 per cent)", "Adverse Events 2:", "Total: 27/213 (12.68%)", "- Leucocytosis 1/213 (0.47%)", "Atrial fibrillation 1/213 (0.47%)", "Congestive heart failure 1/213 (0.47%)", "Pericardial infusion 0/213 (0.00 %)", "Cataract 1/213 (0.47%)", "- Macular Fibrosis 1/213 (0.47%)", "Constipation 1/213 (0.47%)", "Diarrhoea 1/213 (0.47%)", "Enterocolitis 1/213 (0.47%)", "Ileus 0/213 (0.00 %)", "- Nausea 0/213 (0.00 %)"]}